| Description |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Bevacizumab 100mg/4ml |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Bevacizumab 400mg/16ml |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Atezolizumab 1200mg/20ml |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Pertuzumab 420mg/14ml |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Searle Pharma |
|
| Product Type |
Product Size |
| Tablets |
30'S |
| Product Company |
| Beacon Pharmaceuticals |
Sorafenib 200mg |
| Content | "
Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. | "
Bevacizumab is a type of targeted cancer drug treatment. It is also known as Avastin. It is a treatment for a number of different cancer types. | "
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and alveolar soft part sarcoma. | "
Pertuzumab is a monoclonal antibody. . Monoclonal antibodies work by attaching to proteins on or in cancer cells. Human epidermal growth factor 2 (HER2) is a protein that makes cells grow and divide. | Rituximab, an anti CD20 monoclonal antibody, is used in the management of lymphoproliferative and autoimmune conditions. | Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent.
|
Reviews
There are no reviews yet.